Real-life Use of Bexarotene for T-cell Cutaneous Lymphoma Management: Efficacy and Tolerance with Low Doses

Authors

  • Jacques Rouanet Dermatology and Oncodermatology Department, CHU Clermont-Ferrand, Université Clermont Auvergne, F-63000 Clermont-Ferrand, France
  • Ines Joulie Dermatology and Oncodermatology Department, CHU Clermont-Ferrand, Université Clermont Auvergne, F-63000 Clermont-Ferrand, France
  • Celine Lambert DRCI, Biostatistics Unit, CHU Clermont-Ferrand, F-63000 Clermont-Ferrand, France
  • Michel D'Incan Dermatology and Oncodermatology Department, CHU Clermont-Ferrand, Université Clermont Auvergne, F-63000 Clermont-Ferrand, France

DOI:

https://doi.org/10.2340/actadv.v102.718

Keywords:

bexarotene, T-cell cutaneous lymphoma, mycosis fungoides, Sezary syndrome, depression

Abstract

Abstract is missing (Short communication)

Downloads

Download data is not yet available.

References

Willemze R, Cerroni L, Kempf W, Berti E, Facchetti F, Swerdlow SH, et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood 2019; 133: 1703-1714.

https://doi.org/10.1182/blood-2018-11-881268 DOI: https://doi.org/10.1182/blood-2018-11-881268

Duvic M, Hymes K, Heald P, Breneman D, Martin AG, Myskowski P, et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol 2001; 19: 2456-2471.

https://doi.org/10.1200/JCO.2001.19.9.2456 DOI: https://doi.org/10.1200/JCO.2001.19.9.2456

Sokolowska-Wojdylo M, Florek A, Zaucha JM, Chmielowska E, Giza A, Knopinska-Posluszny W, et al. Polish Lymphoma Research Group experience with bexarotene in the treatment of cutaneous t-cell lymphoma. Am J Ther 2016; 23: e749-756.

https://doi.org/10.1097/MJT.0000000000000056 DOI: https://doi.org/10.1097/MJT.0000000000000056

Quereux G, Saint-Jean M, Peuvrel L, Brocard A, Knol AC, Dreno B. Bexarotene in cutaneous T-cell lymphoma: third retrospective study of long-term cohort and review of the literature. Expert Opin Pharmacother 2013; 14: 1711-1721.

https://doi.org/10.1517/14656566.2013.810718 DOI: https://doi.org/10.1517/14656566.2013.810718

Väkevä L, Ranki A, Hahtola S. Ten-year experience of bexarotene therapy for cutaneous T-cell lymphoma in Finland. Acta Derm Venereol 2012; 92: 258-263.

https://doi.org/10.2340/00015555-1359 DOI: https://doi.org/10.2340/00015555-1359

Abbott RA, Whittaker SJ, Morris SL, Russell-Jones R, Hung T, Bashir SJ, et al. Bexarotene therapy for mycosis fungoides and Sezary syndrome. Br J Dermatol 2009; 160: 1299-1307.

https://doi.org/10.1111/j.1365-2133.2009.09037.x DOI: https://doi.org/10.1111/j.1365-2133.2009.09037.x

Roche Gamon E, Perez Ferriols A, Vilata Corell JJ, Alegre de Miquel V. [Mycosis fungoid treated with oral bexarotene: study of 13 cases]. Med Clin (Barc) 2007; 129: 677 (in Spanish).

https://doi.org/10.1157/13112095 DOI: https://doi.org/10.1157/13112095

Fujimura T, Sato Y, Tanita K, Amagai R, Shimauchi T, Ogata D, et al. Case series of cutaneous T-cell lymphomas treated with bexarotene-based therapy. J Dermatol 2020; 47: 636-640.

https://doi.org/10.1111/1346-8138.15322 DOI: https://doi.org/10.1111/1346-8138.15322

Gniadecki R, Assaf C, Bagot M, Dummer R, Duvic M, Knobler R, et al. The optimal use of bexarotene in cutaneous T-cell lymphoma. Br J Dermatol 2007; 157: 433-440.

https://doi.org/10.1111/j.1365-2133.2007.07975.x DOI: https://doi.org/10.1111/j.1365-2133.2007.07975.x

Downloads

Published

2022-07-07

How to Cite

Rouanet, J., Joulie, I., Lambert, C., & D’Incan, M. (2022). Real-life Use of Bexarotene for T-cell Cutaneous Lymphoma Management: Efficacy and Tolerance with Low Doses. Acta Dermato-Venereologica, 102, adv00746. https://doi.org/10.2340/actadv.v102.718

Issue

Section

Short Communication

Categories